Candel Therapeutics files new $50 million at-the-market stock sale agreement with Jefferies
Candel updated its sales arrangement with Jefferies on November 12, 2026, after fully using up its prior $50 million agreement.
Candel Therapeutics filed a prospectus supplement dated November 12, 2026 covering a new at-the-market stock sale arrangement with Jefferies LLC. The company amended and restated its prior sale agreement on November 12, 2026 by entering into a Second Amended and Restated Open Market Sale Agreement with Jefferies.1
The move followed full use of the previous facility. Candel had previously filed a prospectus dated August 22, 2025 for the offer and sale of common stock up to $50,000,000 through Jefferies, and as of the date of the new supplement had sold the full $50,000,000 under that prior prospectus.1 As a result, the offering under the prior prospectus was terminated and no further shares will be sold under it.1
The new agreement provides for the offer and sale of common stock with an aggregate offering price of up to $50,000,000 over time through Jefferies, acting as sales agent or principal.1 Jefferies will be compensated at a fixed commission rate of 3.0% of gross proceeds from shares sold under the agreement.1
As of the filing, Candel's common stock trades on the Nasdaq Global Market under the symbol CADL, closing at $9.22 per share on November 11, 2026.1 The company said it currently intends to use net proceeds primarily for working capital and general corporate purposes, including research and development, manufacturing, clinical trials, pre-commercialization and commercialization activities, and general and administrative and capital expenditures.1
The filing noted potential dilution from the offering: assuming a sale of 5,422,993 shares at $9.22 per share for aggregate proceeds of $48,225,000 after fees, investors would experience immediate dilution of $7.08 per share1 relative to adjusted net tangible book value. The supplement is part of a shelf registration under which Candel may offer securities with an aggregate offering price of up to $300,000,000.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.